Compare CLMB & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | AVIR |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.8M | 450.9M |
| IPO Year | 1996 | 2020 |
| Metric | CLMB | AVIR |
|---|---|---|
| Price | $22.75 | $5.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $80.00 | $10.00 |
| AVG Volume (30 Days) | 148.9K | ★ 354.3K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ 14.29 | 3.00 |
| EPS | ★ 4.64 | N/A |
| Revenue | ★ $652,517,000.00 | $351,367,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | ★ 40.14 | N/A |
| 52 Week Low | $19.16 | $2.46 |
| 52 Week High | $145.00 | $6.45 |
| Indicator | CLMB | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 16.43 | 55.86 |
| Support Level | $19.16 | $3.28 |
| Resistance Level | $130.07 | $6.37 |
| Average True Range (ATR) | 0.96 | 0.24 |
| MACD | 2.95 | -0.02 |
| Stochastic Oscillator | 81.98 | 60.97 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.